Table 1 Patient and Treatment characteristics of complete cohort
Total (n = 273) | |
|---|---|
No. (%) | |
Sex | |
Female | 110 (40.3%) |
Male | 163 (59.7%) |
Histology | |
Undifferentiated pleomorphic sarcoma | 56 (8.1%) |
Undifferentiated spindle cell sarcoma | 30 (11%) |
Undifferentiated sarcoma nos | 22 (20.5%) |
Fibrosarcoma | 5 (1.8%) |
Myxofibrosarcoma | 44 (16.1%) |
Liposarcoma nos | 7 (2.6%) |
Myxoid liposarcoma | 26 (9.5%) |
Pleomorphic liposarcoma | 8 (2.9%) |
Mixed liposarcoma | 8 (2.9%) |
Dedifferentiated liposarcoma | 16 (5.9%) |
Leiomyosarcoma | 17 (6.2%) |
Myxoid leiomyosarcoma | 2 (0.7%) |
Synovial sarcoma | 23 (8.5%) |
Angiosarcoma | 5 (1.8%) |
Malignant peripheral nerve sheath tumor | 3 (1.1%) |
Small round cell sarcoma | 1 (0.4%) |
Surgery | 267 (97.8%) |
Radiation | 220 (80.6%) |
Chemotherapy role | |
None | 206 (75.5%) |
Neoadjuvant | 56 (20.5%) |
Adjuvant | 8 (2.9%) |
Both | 3 (1.1%) |
Type of chemotherapy | |
None | 206 (75.5%) |
MAI | 53 (19.4%) |
MAI → gemcitabine/docetaxel | 1 (0.4%) |
MAID | 5 (1.8%) |
Dacarbazine/doxorubicin | 4 (1.5%) |
Paclitaxel | 2 (0.7%) |
Gemcitabine/docetaxel | 1 (0.4%) |
Unknown | 1 (0.4%) |
Median (range) | |
|---|---|
Age at diagnosis (years) | 64 (24–97) |
Path tumor size (cm) | 9.7 (5–43.5) |
Median follow-up in living patients (months) | 51 (3–181) |